Raptor Pharmaceutical Corp. Upgraded to Trade on the NASDAQ Global Market
Raptor Pharmaceutical Corp.
02.03.2012 12:30
---------------------------------------------------------------------------
Company to Present at the 32nd Annual Cowen Health Care Conference
NOVATO, Calif., 2012-03-02 12:30 CET (GLOBE NEWSWIRE) --
Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today
announced that the Company has been upgraded to trade on the NASDAQ Global
Market. Shares of Raptor's common stock began trading on the NASDAQ Global
Market on February 29, 2012 and will continue to be traded under the ticker
RPTP.
'As we continue to make progress towards potentially commercializing our first
product, we see this as reinforcement that we have also progressed as a
corporate entity since listing on the NASDAQ Capital Market,' said Kim R.
Tsuchimoto, Chief Financial Officer, Treasurer and Secretary of Raptor. 'We
believe the move to the NASDAQ Global Market could bring increased market
exposure and liquidity to our shares among those who recognize and appreciate
our ability to meet the listing qualifications for the NASDAQ Global Market.'
The Company also announced that Christopher M. Starr, Ph.D., the Company's
Chief Executive Officer, will present an overview of the company at the 32nd
Annual Cowen Health Care Conference. Raptor's presentation will take place at
the Boston Marriott Copley Place on Wednesday, March 7th at 9:20am ET.
A live audio webcast and 14-day archive of the Cowen presentation will be
available at http://ir.raptorpharma.com/events.cfm
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ('Raptor') seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis ('NASH'), Huntington's Disease ('HD'), aldehyde dehydrogenase
deficiency ('ALDH2'), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180
Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser@troutgroup.com
EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo@evcgroup.com
News Source: NASDAQ OMX
02.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Raptor Pharmaceutical Corp.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Raptor Pharmaceutical Corp.
02.03.2012 12:30
---------------------------------------------------------------------------
Company to Present at the 32nd Annual Cowen Health Care Conference
NOVATO, Calif., 2012-03-02 12:30 CET (GLOBE NEWSWIRE) --
Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today
announced that the Company has been upgraded to trade on the NASDAQ Global
Market. Shares of Raptor's common stock began trading on the NASDAQ Global
Market on February 29, 2012 and will continue to be traded under the ticker
RPTP.
'As we continue to make progress towards potentially commercializing our first
product, we see this as reinforcement that we have also progressed as a
corporate entity since listing on the NASDAQ Capital Market,' said Kim R.
Tsuchimoto, Chief Financial Officer, Treasurer and Secretary of Raptor. 'We
believe the move to the NASDAQ Global Market could bring increased market
exposure and liquidity to our shares among those who recognize and appreciate
our ability to meet the listing qualifications for the NASDAQ Global Market.'
The Company also announced that Christopher M. Starr, Ph.D., the Company's
Chief Executive Officer, will present an overview of the company at the 32nd
Annual Cowen Health Care Conference. Raptor's presentation will take place at
the Boston Marriott Copley Place on Wednesday, March 7th at 9:20am ET.
A live audio webcast and 14-day archive of the Cowen presentation will be
available at http://ir.raptorpharma.com/events.cfm
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ('Raptor') seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis ('NASH'), Huntington's Disease ('HD'), aldehyde dehydrogenase
deficiency ('ALDH2'), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180
Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser@troutgroup.com
EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo@evcgroup.com
News Source: NASDAQ OMX
02.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Raptor Pharmaceutical Corp.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------